BioNTech SE (Nasdaq: BNTX, “BioNTech”), a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, and Autolus Therapeutics plc (Nasdaq: AUTL, “Autolus”), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a strategic collaboration aimed at advancing…
At an upcoming presentation at the RSVVW’24 conference, Moderna will share follow-up data from its ongoing ConquerRSV Phase 3 study of its investigational RSV vaccine candidate, mRNA-1345. As previously published in the New England Journal of Medicine, the primary analysis from…
Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE PFE) have announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for tisotumab vedotin, an antibody-drug conjugate (ADC), intended for the treatment of adult patients with recurrent…
Bio-Techne Corporation (NASDAQ: TECH) has unveiled a groundbreaking achievement, as its spatial biology brand, Advanced Cell Diagnostics (ACD), sets a new industry standard. The innovation comes in the form of a cutting-edge, protease-free RNAscope spatial multiomics workflow, designed for superior…
Vivet Therapeutics Secures EUR 4.9 Million Government Funding for Gene Therapy Advancement in Cerebrotendinous Xanthomatosis Treatment” Vivet Therapeutics, a biotech company specializing in gene therapies for rare inherited metabolic disorders, has received EUR 4.9 million in funding from the French…
Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), today announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, which demonstrated pharmacologic hearing restoration within 30 days of AK-OTOF administration in the first participant, an individual…
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU) to be held from January 25-27 in San Francisco, California, highlighting the company’s progress in making long-term…
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today launched its “Optimising biotech funding” whitepaper. This provides an overview of the current state of play for biotech companies and the research and development (R&D) strategies they can…
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, have announced the initiation of GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002 (also known…
Sail Biomedicines, Inc., a Flagship Pioneering company and leader in RNA-based programmable medicines, today provided an update on its research funded by the Cystic Fibrosis Foundation (CF Foundation), with preclinical data that suggest that Sail’s Endless RNA™ (eRNA™) may offer…
The first patient has been dosed in two global, randomized phase 3 trials evaluating the efficacy and safety of Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) datopotamab deruxtecan (Dato-DXd) in combination with durvalumab, AstraZeneca’s anti-PD-L1 therapy, in two types…
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that its corporate venture capital (CVC) subsidiary in the U.S.A., “Chugai Venture Fund, LLC” (CVF) finalized establishment of a $200M venture fund based in the Boston area, MA with a well-experienced head in key…